Abstract 600TiP
Background
c-Met (MET protein) is overexpressed (OE) in ∼25% of patients (pts) with EGFR WT NSQ NSCLC (Ansell. CRUK 2022). In the phase 2 LUMINOSITY study (NCT03539536), Teliso-V, a c-Met–directed antibody-drug conjugate, had an overall response rate of 52% in c-MET high OE pts (37% in all [intermediate + high OE] pts) with previously treated EGFR WT NSQ NSCLC with an acceptable safety profile; ORR was 86% in a subanalysis of Asian pts with high c-MET OE (58% in all pts) (Horinouchi. JSMO 2023). Teliso-V warrants further investigation, including in Asian pts.
Trial design
TeliMET NSCLC-01 (NCT04928846) is a global, open-label, randomized phase 3 trial evaluating if Teliso-V has better efficacy vs current standard of care (docetaxel) in pts with c-Met OE (central lab testing using VENTANA MET [SP44] RxDx Assay [Investigational Use Only (IUO) device], Ventana Medical Systems), EGFR WT, NSQ, a/mNSCLC. Key eligibility criteria include aged ≥18 and ECOG performance status 0–1. Pts must have progressed on at least 1 prior line of therapy for a/mNSCLC, which includes no more than 1 line of prior platinum-containing systemic chemotherapy and must be c-Met antibody and docetaxel naive. Pts will be randomized 1:1 to receive Teliso-V (1.9 mg/kg Q2W) or docetaxel (75 mg/m2 Q3W) monotherapy until disease progression/met study discontinuation criteria. The co-primary endpoints are progression-free survival (per independent central review [ICR]) and overall survival. Secondary endpoints include objective response rate, duration of response (both per ICR), and pt-reported outcomes. Safety and tolerability assessments include adverse events (AEs), and drug discontinuation/dose modifications due to AEs. Pharmacokinetic parameters as well as biomarkers and their correlation to clinical responses will be assessed. Subgroup analysis will be conducted for Asian pts. Enrollment of ≥698 pts is planned across ∼300 sites in ∼40 countries. As of 4 July 2023, 162 sites are actively recruiting in 26 countries including Asia-Pacific countries (China [25 sites], Japan [38 sites], South Korea [5 sites], Taiwan [8 sites], Australia [2 sites]).
Clinical trial identification
NCT04928846.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. No honoraria or payments were made for authorship.
Disclosure
J. Tanizaki: Financial Interests, Personal, Invited Speaker: AstraZeneca K.K., Boehringer Ingelheim Japan Inc, Bristol Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., MSD K.K, Nihon Medi-Physics Co. Ltd., Nippon Kayaku Co. Ltd., Taiho; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim Japan. H. Akamatsu: Financial Interests, Personal, Other, Lecturer: MSD KK, Eli Lilly Japan KK, Amgen Inc Lecture, Chugai Pharmaceutical Co Ltd, Ono Pharmaceutical Co Ltd, AstraZeneca KK, Boehringer Ingelheim Japan Inc, Bristol Myers Squibb Co Ltd, Novartis Pharma KK, Taiho Pharmaceutical Co Ltd, Pfizer Japan Inc, Nippon ; Financial Interests, Personal, Research Grant: MSD KK, Eli Lilly Japan KK, and Amgen Inc. J. Su: Financial Interests, Personal, Invited Speaker: AstraZeneca, Taiwan, Boehringer Ingelheim, Taiwan, Chugai Pharmaceutical Co., Taiwan, MSD, Taiwan, F. Hoffmann-La Roche, Taiwan, Ono Pharmaceutical, Taiwan, Pfizer, Taiwan. M.S. Xia, B. Ainsworth, M. Li, E. Bolotin, J. Seraj: Financial Interests, Personal, Stocks/Shares: AbbVie Inc. S. Lu: Financial Interests, Personal, Research Funding: AstraZeneca, Hutchison MediPharma, BMS, Hengrui Therapeutics, BeiGene, Roche, Hansoh; Financial Interests, Personal, Other, Speaker fees: AstraZeneca, Roche, Hansoh, Hengrui Therapeutics; Financial Interests, Personal, Advisory Role: AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, Simcere, Zai Lab, GenomiCare, Yuhan Corporation, prIME Oncology, Menarini, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract